Skip to main content

Featured

Ontario Hydro Rates Drop November 1, But Your Bill Might Not

  Ontario Hydro Rates Drop November 1, But Your Bill Might Not Ontario electricity prices are changing on Sunday, November 1, 2026. The Ontario Energy Board (OEB) has announced lower regulated electricity rates for households, small businesses and farms. But there is a catch: the provincial electricity rebate is also shrinking, meaning lower electricity prices will not necessarily translate into lower overall bills. For Ontario households already dealing with higher grocery prices, mortgage payments and winter heating costs, understanding these changes could help save money over the coming months. Here is what you need to know about the new rates, how to choose between Time-of-Use, Tiered and Ultra-Low Overnight pricing, and the winter protection that prevents electricity disconnections for non-payment. 1. Ontario Electricity Rates Change November 1 The new rates take effect November 1, bringing lower prices for electricity used under Ontario's Regulated Price Plan (RPP). Accordin...
Post a Comment
Read more

article

Labels

Alzheimer’s Drug Donanemab Receives FDA Advisers’ Endorsement for Slowing Disease Progression

 

A significant milestone has been reached in the fight against Alzheimer’s disease. Eli Lilly’s closely watched Alzheimer’s drug, donanemab, has won the unanimous backing of federal health advisers. The drug is specifically intended for people with mild dementia caused by this brain-robbing disease.

The decision by the Food and Drug Administration (FDA) advisers comes after careful consideration of the drug’s benefits and risks. Donanemab has demonstrated the ability to modestly slow cognitive decline and memory problems associated with Alzheimer’s. Although it’s not a cure, this endorsement represents a promising step forward in managing the disease.

Here are the key points:

  1. Effectiveness: Donanemab has shown effectiveness in slowing cognitive decline. Patients who received monthly intravenous infusions of the drug declined about 35% more slowly than those who received a placebo.
  2. Risk Assessment: The FDA panel weighed the risks, including side effects like brain swelling and bleeding, which will need monitoring. Despite these risks, the panel concluded that the drug’s benefits outweighed them.
  3. Tau Protein Screening: Unlike previous concerns about tau protein screening, most panelists believed there was enough evidence to prescribe the drug broadly without requiring such screening.
  4. FDA Decision: The FDA will make the final decision on approval later this year. If approved, donanemab would become only the second Alzheimer’s drug in the U.S. shown to convincingly slow cognitive decline.

This endorsement brings hope to individuals and families affected by Alzheimer’s, and we eagerly await the FDA’s final decision. Stay tuned for further updates on this groundbreaking development! 

Labels:

Comments

Post a Comment